Foundayo Guide
Foundayo (orforglipron) was the first small-molecule GLP-1 receptor agonist to win FDA approval in an oral once-daily form for chronic weight management. That approval landed on April 1, 2026. One tablet a day, with or without food, marking a major change from injectable GLP-1s and from oral semaglutide (Rybelsus), which has strict food and water rules. In the 72-week ATTAIN-1 phase 3 trial, the highest dose produced 11.1% mean weight loss versus 2.1% on placebo (FDA label, all randomized patients).
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
At a Glance
| Generic Name | Orforglipron |
| Brand Names | Foundayo |
| FDA Status | FDA-approved for chronic weight management in adults with obesity, or overweight with weight-related medical problems, alongside a reduced-calorie diet and increased physical activity (April 1, 2026). Not approved for pediatric use. Cannot be used with other GLP-1 receptor agonists.[1] |
| Approval Date | April 1, 2026[1] |
How does Foundayo work?
Orforglipron is not built as a peptide. It is a small organic molecule that binds the GLP-1 receptor and switches it on directly. Unlike injectable GLP-1 peptides (semaglutide, tirzepatide) or oral peptide formulations (Rybelsus and Ozempic tablets), orforglipron is a true small organic molecule that survives stomach acid and digestion, eliminating the need for injection or special food restrictions. It produces the same downstream effects as injectable GLP-1 agonists: appetite suppression, slowed gastric emptying, and reduced food reward signaling.[2]
Dosing Schedule
Foundayo uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].
What side effects does Foundayo cause?
Common: nausea, constipation, diarrhea, vomiting, indigestion, abdominal pain, headache, swollen belly, fatigue, belching, heartburn, gas, hair loss. Serious: pancreatitis, dehydration leading to kidney problems, gallbladder disease, hypoglycemia (especially with insulin/sulfonylureas), serious allergic reactions, diabetic retinopathy progression in T2D patients, increased aspiration risk during anesthesia. Boxed warning: risk of thyroid C-cell tumors. Other GLP-1 drugs caused these tumors in rats and mice; orforglipron is not active in rodents and did not produce them, and whether the finding applies to humans has not been determined. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).[1][2]
Nothing above is the full list. Your prescriber can give you the complete safety picture, and every adverse reaction on record sits in the current FDA prescribing information[1].
Clinical Trial Results
ATTAIN-1 (NCT05869903; Wharton et al. NEJM 2025, PMID 40960239) ran 72 weeks at sites in 10 countries: phase 3, randomized, placebo-controlled, 3,127 adults, all of them obese or overweight carrying a weight-related comorbidity, none of them diabetic. The highest dose produced 11.1% mean body weight reduction (~25 lbs) versus 2.1% on placebo in all randomized patients (FDA label; the paper reports 11.2%). The trial dosed an investigational formulation at 6, 12 and 36 mg; the label converts these to the marketed 5.5, 9 and 17.2 mg tablets. Improvements were seen in waist size, systolic blood pressure, triglycerides and non-HDL cholesterol. ATTAIN-2 (NCT05872620; Horn et al. Lancet 2026, PMID 41275875), in 1,613 adults with type 2 diabetes, is complete: the highest dose cut body weight 9.6% versus 2.5% on placebo at 72 weeks.[2]
Where can you get Foundayo?
Sellers in our register that will dispense orforglipron, or a compounded version of it, after an online consultation — shipped to your door.
Editorial score · methodology
Editorial score · methodology
Found
Best for: people who want clinician visits billed to commercial insurance, with compounded medication in the plan price
Editorial score · methodology
Editorial score · methodology
LillyDirect
Best for: brand-name Zepbound or Foundayo bought from the manufacturer at a posted cash price
Editorial score · methodology
Editorial score · methodology
How much does Foundayo cost?
27 sellers in the register publish a price; the lowest starts at $149 a month, checked November 2026. What each one charges to start, cheapest at the top. Compounded orforglipron from state-licensed 503A pharmacies is legal under federal compounding law when made for an individual patient[3], and the rules loosen further, to include bulk compounding by 503B outsourcing facilities, only while a molecule sits on the FDA Drug Shortage List[4]. An FSA or HSA will generally cover either kind of prescription, compounded or branded, under IRS Publication 502[5]. What you actually pay moves with your dose and with whatever promotion happens to be running.
| Provider | Starting Price | Link | |
|---|---|---|---|
| Amazon One Medical | brand | $149/mo + visit fee | Visit |
| Found | brand | $149/mo + membership | Visit |
| GoodRx | brand | $149/mo | Visit |
| Healthspan | brand | $149/mo + membership | Visit |
| Hims | brand | $149/mo + membership | Visit |
| Imbue Health | brand | $149/mo + membership | Visit |
| Intermountain Health On-Demand Weight Loss | brand | $149/mo + consult fee | Visit |
| Knownwell | brand | $149/mo + visit fee | Visit |
| LillyDirect | brand | $149/mo | Visit |
| médetone | brand | $149/mo + membership | Visit |
Show all 27 Foundayo sellersShowing all 27 sellers
| Mochi Health | brand | $149/mo + membership | Visit |
| PreventiveMD | brand | $149/mo | Visit |
| Ro | brand | $149/mo + membership | Visit |
| Sculpt Rx | brand | $149/mo + membership | Visit |
| Sesame Care | brand | $149/mo + care fee | Visit |
| ShedRx | brand | $149/mo + membership | Visit |
| Walgreens Weight Management | brand | $149/mo + visit fee | Visit |
| WeightWatchers Clinic | brand | $149/mo + membership | Visit |
| ZipHealth | brand | $149/mo + fees | Visit |
| Maximus | brand | $199.99/mo | Visit |
| Alloy | brand | $248/mo | Visit |
| Phoenix NP | brand | $248/mo | Visit |
| SkinnyRx | brand | $248/mo | Visit |
| CLYR Health | brand | $329/mo | Visit |
| Näky | brand | $424/mo + membership | Visit |
| Pallas Health | brand | $499/mo | Visit |
| Immortals | brand | $750/mo, prepaid | Visit |
Foundayo Head-to-Head Comparisons
Short verdict pages setting Foundayo against the other GLP-1 options, working from the trial results, the dose ladders on each label, and what the manufacturers charge today.
See all drug-vs-drug verdicts.
Foundayo Patient Questions, Answered
Questions people actually asked about Foundayo in named subreddits, each answered from the published trial data.
Foundayo Reference Cards
One-screen references for the dose schedule, what to do about a missed dose, and the side effects that warrant a call. Every figure checked against the DailyMed label.
Related Research on Foundayo
Longer pieces written here, built on the trial papers themselves, checked against the FDA label, and argued rather than summarized.
Frequently Asked Questions
Sources & methodology — as of November 2026
- 1.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 2.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 3.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 4.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 5.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
Glossary
The words sellers use, defined. Tap any term.
- Orforglipron · Drugs and brands
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- GLP-1 receptor · Mechanism